Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.47 |
| ▸ | HTR2B | P41595 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.36 |
| ▸ | SLC9A2 | Q9UBY0 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11962360 | 0.82 | SLC9A1 (0.50) | LMNATRPA1CHRM1SLC6A2ADRA1A | |
| SCHEMBL1929488 | 0.81 | TRPV4 (0.44) | LMNATRPA1ALDH1A1TRPV4HPGD | |
| SCHEMBL29926173 | 0.81 | LMNA (0.52) | LMNATRPA1CHRM1SLC6A2ADRA1A | |
| SCHEMBL28654214 | 0.81 | LMNA (0.52) | LMNATRPA1CHRM1SLC6A2ADRA1A | |
| SCHEMBL1979988 | 0.81 | LMNA (0.52) | LMNATRPA1CHRM1SLC6A2ADRA1A | |
| SCHEMBL29876673 | 0.79 | LMNA (0.46) | LMNATRPA1CHRM1SLC6A2ADRA1A | |
| SCHEMBL25759570 | 0.79 | L3MBTL1 (0.39) | ALDH1A1GAATRPV4HPGDSLC9A1 | |
| SCHEMBL2180670 | 0.79 | LMNA (0.46) | LMNATRPA1CHRM1SLC6A2ADRA1A | |
| Potassium Ion SCHEMBL29661152 | 0.79 | LMNA (0.50) | LMNATRPA1CHRM1SLC6A2ADRA1A | |
| SCHEMBL29627448 | 0.77 | TRPV4 (0.42) | ALDH1A1GAATRPV4HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230174523-A1 | BENZENESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF | AMATHUS THERAPEUTICS, INC. (US) | 2023-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230174523-A1 | BENZENESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF | TRAP1, PINK1, TP53BP1 | LMNA 3435/4885TRPA1 845/4885CHRM1 1808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.